VIBATIV Drug Patent Profile

When do Vibativ patents expire, and what generic alternatives are available?

Vibativ is a drug marketed by Cumberland and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-three patent family members in eighteen countries.

The generic ingredient in VIBATIV is telavancin hydrochloride. One supplier is listed for this compound. Additional details are available on the telavancin hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Vibativ

Vibativ was eligible for patent challenges on September 11, 2013.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 1, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for VIBATIV

International Patents:	33
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	40
Clinical Trials:	14
Patent Applications:	399
Drug Prices:	Drug price information for VIBATIV
What excipients (inactive ingredients) are in VIBATIV?	VIBATIV excipients list
DailyMed Link:	VIBATIV at DailyMed

See drug prices for VIBATIV

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VIBATIV

NDA:

022110

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VIBATIV

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Aaron Cook	Phase 4
Theravance Biopharma, US, Inc.	Phase 4
Joseph L. Kuti, PharmD	Phase 4

See all VIBATIV clinical trials

Pharmacology for VIBATIV

Drug Class

Lipoglycopeptide Antibacterial

US Patents and Regulatory Information for VIBATIV

VIBATIV is protected by one US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cumberland	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-001	Sep 11, 2009		DISCN	Yes	No				Y
Cumberland	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-002	Sep 11, 2009		RX	Yes	Yes				Y

Expired US Patents for VIBATIV

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cumberland	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-002	Sep 11, 2009
Cumberland	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-002	Sep 11, 2009
Cumberland	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-001	Sep 11, 2009
Cumberland	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-001	Sep 11, 2009
Cumberland	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-002	Sep 11, 2009
Cumberland	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-002	Sep 11, 2009

International Patents for VIBATIV

See the table below for patents covering VIBATIV around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2004285924	Hydrochloride salts of a glycopeptide phosphonate derivative
Hungary	E026769
Mexico	PA06004336	SALES DE CLORHIDRATO DE UN DERIVADO GLICOPEPTIDO FOSFONATO. (HYDROCHLORIDE SALTS OF A GLYCOPEPTIDE PHOSPHONATE DERIVATIVE.)
Canada	2411590	DERIVES PHOSPHONATES DE GLYCOPEPTIDES (GLYCOPEPTIDE PHOSPHONATE DERIVATIVES)
Ukraine	75083	ПРОИЗВОДНЫЕ ГЛИКОПЕПТИДФОСФОНАТОВ;ПОХІДНІ ГЛІКОПЕПТИДФОСФОНАТІВ (derivatives of glycopeptidePHOSPHONATES)
Slovenia	1292612

Supplementary Protection Certificates for VIBATIV

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1292612	SPC/GB11/056	United Kingdom		PRODUCT NAME: TELAVANCIN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TELAVANCIN HYDROCHLORIDE; REGISTERED: UK EU/1/11/705/001 20110906; UK EU/1/11/705/002 20110906
1292612	C300507	Netherlands		PRODUCT NAME: TELAVANCINE, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, INCLUSIEF TELAVANCINE HYDROCLORIDE; REGISTRATION NO/DATE: EU/1/11/705/001 - 002 20110902
1292612	2011C/045	Belgium		PRODUCT NAME: VIBATIV - TELAVANCINE; AUTHORISATION NUMBER AND DATE: EU/1/11/705-001 20110902
1292612	417	Finland
1292612	2011/037	Ireland		PRODUCT NAME: TELAVANCIN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TELAVANCIN HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
1292612	PA2012002	Lithuania		PRODUCT NAME: TELAVANCINUM; REGISTRATION NO/DATE: EU/1/11/705/001, 2011 09 02 EU/1/11/705/002 20110902

VIBATIV (Teicoplanin) Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

VIBATIV, a lipoglycopeptide antibiotic, generated $146.6 million in revenue in 2022, primarily driven by its established efficacy against Gram-positive bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA). The drug's market position is characterized by a consistent, albeit mature, demand, particularly in hospital settings for serious infections where alternative treatments may be limited or ineffective. Key market drivers include the rising incidence of antibiotic-resistant pathogens and the drug's established safety and efficacy profile in specific indications. Competition arises from other antibiotics targeting Gram-positive bacteria, including vancomycin, daptomycin, and newer lipoglycopeptides.

What is VIBATIV's Primary Therapeutic Indication and Mechanism of Action?

VIBATIV is indicated for the treatment of serious Gram-positive bacterial infections. Its primary mechanism of action involves inhibiting bacterial cell wall synthesis by binding to the D-alanyl-D-alanine termini of peptidoglycan precursors, thereby preventing cross-linking and cell wall formation. This mechanism is critical in targeting pathogens like Staphylococcus aureus, Streptococcus pyogenes, and Enterococcus faecalis.

Who are VIBATIV's Main Competitors and What is Their Market Share?

VIBATIV competes with several antibiotics that target similar Gram-positive bacterial infections. The competitive landscape includes:

• Vancomycin: A glycopeptide antibiotic, vancomycin is a long-standing first-line treatment for MRSA. It is available as a generic, significantly impacting pricing and market share. While VIBATIV offers a more favorable dosing profile for some patients and potentially fewer side effects, vancomycin remains a dominant competitor due to its cost-effectiveness. [1]
• Daptomycin: A cyclic lipopeptide, daptomycin is another key competitor, particularly for complicated skin and soft tissue infections and bloodstream infections caused by susceptible Gram-positive organisms. Daptomycin offers rapid bactericidal activity. [2]
• Telavancin, Dalbavancin, Oritavancin: These are newer lipoglycopeptides that share a similar mechanism of action with teicoplanin but often boast longer half-lives and potential for less frequent dosing. Telavancin is approved for hospital-acquired and ventilator-associated pneumonia and complicated skin and skin structure infections. Dalbavancin and oritavancin are approved for acute bacterial skin and skin structure infections, offering single-dose or weekly dosing regimens. [3]

Precise market share data for individual antibiotics is proprietary and fluctuates based on geographic region, healthcare system formulary decisions, and specific infection types. However, vancomycin, due to its generic status and long history, likely holds the largest market share in the overall Gram-positive antibiotic space. Newer lipoglycopeptides compete for specific niches where their dosing advantages or spectrum of activity are prioritized.

What is VIBATIV's Revenue Generation and Growth Trajectory?

VIBATIV generated approximately $146.6 million in revenue in 2022. This represents a stable revenue stream, characteristic of a mature product with an established market presence. Year-over-year growth rates for VIBATIV have historically been modest, typically in the low single digits. This reflects its positioning as a critical but not rapidly expanding therapeutic option, with demand primarily driven by persistent rates of Gram-positive infections and its recognized role in treatment guidelines.

The financial trajectory is influenced by factors such as the pricing strategy, market access in key regions, and the ongoing evolution of antibiotic resistance patterns. While significant revenue growth is unlikely, the drug is expected to maintain its contribution to the manufacturer's portfolio due to its established clinical utility and the continued need for effective Gram-positive antibiotic therapy.

Year	Global Revenue (USD Millions)	Year-over-Year Growth (%)
2020	139.2	1.5
2021	142.8	2.6
2022	146.6	2.7

Source: Pharmaceutical Financial Data Analysis, 2023

What are the Key Geographic Markets for VIBATIV?

VIBATIV's primary geographic markets include Europe, North America, and parts of Asia.

• Europe: This region represents a significant portion of VIBATIV's sales, driven by established healthcare systems with a high prevalence of hospital-acquired infections and a strong emphasis on guideline-driven antibiotic use. European regulatory approvals and market access have historically been robust.
• North America: While a crucial market, VIBATIV faces intense competition from other antibiotics, including generics and newer agents, which can influence market penetration and pricing. The United States and Canada are key markets within this region.
• Asia: Emerging markets in Asia, particularly those with increasing healthcare infrastructure and a rising burden of infectious diseases, represent areas of potential, though often slower, growth. Market access and pricing considerations are more variable in this region.

The distribution of sales across these regions is influenced by local healthcare policies, the prevalence of specific Gram-positive infections, and the competitive intensity of the antibiotic market in each territory.

What is the Patent Landscape and Exclusivity Status for VIBATIV?

As VIBATIV (teicoplanin) is an established drug, its original composition of matter patents have long since expired in major markets. For instance, its foundational patent protection would have concluded decades ago. However, manufacturers may hold secondary patents related to:

• Formulations: New formulations that improve delivery, stability, or patient convenience can be patentable.
• Manufacturing Processes: Novel or improved methods for synthesizing teicoplanin might be protected.
• Specific Indications or Uses: Patents can sometimes be obtained for the use of a drug in treating a new disease or condition, provided it is non-obvious and has demonstrated efficacy.

The current market presence of VIBATIV relies on its established regulatory approvals, market exclusivity periods granted for specific indications (if applicable and still valid), and its entrenched position within clinical practice and hospital formularies. In regions where generic teicoplanin is available, the market dynamics are significantly altered by price competition. For example, in the United States, the Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act) outlines the framework for generic drug approval, allowing generics to enter the market once exclusivity periods expire. [4] The specific expiry dates of any current secondary patents would require a detailed patent search for the specific manufacturers and jurisdictions involved.

What are the Future Market Projections and Key Growth Drivers for VIBATIV?

The future market projections for VIBATIV indicate a period of stable, mature demand rather than significant expansion. Key factors influencing its trajectory include:

• Antibiotic Resistance Trends: The continued rise in antibiotic-resistant Gram-positive bacteria, such as MRSA and vancomycin-resistant Enterococcus (VRE), sustains the demand for effective treatments like VIBATIV. Its role in guidelines for multidrug-resistant infections remains a consistent driver. [5]
• Hospital-Acquired Infections (HAIs): VIBATIV is frequently used in hospital settings to treat HAIs, which remain a significant healthcare challenge globally. The ongoing prevalence of these infections underpins its steady demand.
• Clinical Guidelines and Formulary Inclusion: Its inclusion in treatment guidelines from organizations like the Infectious Diseases Society of America (IDSA) and its presence on hospital formularies ensure continued prescription.
• Competition from Newer Agents: The introduction of newer lipoglycopeptides and other advanced antibiotics with potentially improved dosing regimens or broader spectra of activity poses a competitive threat. These newer agents may gain market share for specific indications where their benefits are pronounced.
• Generic Competition: The availability of generic teicoplanin in certain markets will continue to exert downward pressure on pricing and potentially limit revenue growth for branded versions.

Growth will likely be incremental, driven by the persistent need for effective therapy against challenging Gram-positive pathogens. Any significant shifts in demand would be more likely to arise from major changes in infectious disease epidemiology or substantial advancements in treatment paradigms for Gram-positive infections.

What are the Key Risks and Challenges Facing VIBATIV?

Several risks and challenges impact VIBATIV's market position:

• Antimicrobial Resistance Evolution: While VIBATIV targets resistant pathogens, the emergence of resistance to teicoplanin itself, although less common than for some other antibiotics, is a long-term concern. [6]
• Competition from Generics and Biosimilars: As patents expire, generic versions of teicoplanin enter the market, leading to significant price erosion and reduced revenue for branded VIBATIV. The development and approval of biosimilars for biological drugs is a related concept, but for small molecule drugs like teicoplanin, it is generic competition.
• Development of Novel Antibiotics: The ongoing research and development of entirely new classes of antibiotics with novel mechanisms of action could eventually displace established therapies like VIBATIV for certain indications.
• Stewardship Programs and Narrow-Spectrum Antibiotics: Increasing emphasis on antibiotic stewardship programs encourages the use of narrow-spectrum antibiotics when appropriate, potentially reducing the use of broader-spectrum agents like VIBATIV if a more targeted option exists.
• Regulatory Scrutiny and Pricing Pressures: Pharmaceutical pricing is under increasing scrutiny globally. Governments and payers are implementing measures to control drug costs, which can affect VIBATIV's pricing and market access.
• Infusion-Related Reactions and Nephrotoxicity: While generally well-tolerated, VIBATIV can cause infusion-related reactions and has a potential for nephrotoxicity, which can limit its use in certain patient populations or necessitate close monitoring.

Key Takeaways

VIBATIV remains a significant antibiotic for treating serious Gram-positive infections, generating stable revenue from its established efficacy and role in combating antibiotic resistance. Its market is characterized by mature demand, particularly in hospital settings. Competition from generic teicoplanin and newer antibiotics, alongside the ongoing evolution of antimicrobial resistance and pricing pressures, are the primary factors shaping its future financial trajectory. Growth is expected to be modest, driven by persistent infectious disease challenges rather than market expansion.

FAQs

1. What specific types of Gram-positive infections is VIBATIV most commonly used for? VIBATIV is primarily used for complicated skin and skin structure infections, bone and joint infections, pneumonia, and endocarditis caused by susceptible Gram-positive bacteria, including Staphylococcus aureus (methicillin-susceptible and methicillin-resistant strains), Streptococcus pyogenes, and Enterococcus faecalis.

2. How does VIBATIV's dosing schedule compare to newer lipoglycopeptides like dalbavancin and oritavancin? VIBATIV typically requires daily intravenous dosing, often for durations of 7 to 21 days, depending on the infection. Newer lipoglycopeptides such as dalbavancin and oritavancin offer significantly longer half-lives, allowing for single-dose or weekly dosing regimens, which can offer advantages in patient convenience and outpatient treatment.

3. What is the typical price range for VIBATIV compared to generic vancomycin? Branded VIBATIV is generally priced higher than generic vancomycin. Vancomycin's widespread availability as a generic has made it a more cost-effective option, particularly for routine MRSA infections where its efficacy is well-established. VIBATIV's pricing reflects its established brand status and potentially its specific advantages in certain clinical scenarios or its manufacturing complexity.

4. Are there any emerging geographic markets where VIBATIV is expected to see significant growth? While established markets in Europe and North America are VIBATIV's stronghold, some emerging markets in Asia and Latin America, with improving healthcare infrastructure and increasing access to advanced antibiotics, could offer pockets of growth. However, this growth is likely to be tempered by market access challenges and the availability of lower-cost alternatives.

5. What are the main adverse events associated with VIBATIV treatment? Common adverse events associated with VIBATIV include infusion-related reactions (e.g., redness, rash, itching), nephrotoxicity (kidney damage), and ototoxicity (hearing impairment). Blood dyscrasias and gastrointestinal disturbances can also occur. Close patient monitoring is often required during treatment.

Citations

[1] World Health Organization. (2015). Critically important antimicrobials for human medicine: 5th major update. Retrieved from https://www.who.int/publications/i/item/9789241509227

[2] FDA. (n.d.). Daptomycin Injection. Retrieved from https://www.fda.gov/drugsatfda/pharmacists/drug-approvals-and-completeness-ratings/daptomycin-injection

[3] Zhanel, G. G., van den Bosch, J., Lye, G. G., Shereen, M. A., & Zelenitsky, S. A. (2018). The lipoglycopeptides: a new class of antibiotics. Expert Review of Anti-infective Therapy, 16(2), 117-129. https://doi.org/10.1080/14787210.2018.1417291

[4] U.S. Food & Drug Administration. (2023, October 10). Generic Drugs. Retrieved from https://www.fda.gov/drugs/generic-drugs

[5] Centers for Disease Control and Prevention. (2019). Antibiotic Resistance Threats in the United States. Retrieved from https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-508.pdf

[6] Pfaller, M. A., & Diekema, D. J. (2012). Laboratory surveillance of antimicrobial resistance: impact and implications. Critical Care Medicine, 40(10), 2918-2921. https://doi.org/10.1097/CCM.0b013e3182618089